Psychotropic medications for adolescents and children

Author/s Antonio Clavenna, Laura Reale, Daniele Piovani, Maurizio Bonarti
Publishing Year 2016 Issue 2016/2 Language Italian
Pages 23 P. 79-101 File size 244 KB
DOI 10.3280/RSF2016-002006
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Though international studies highlight, in Europe, the increase in use of psychotropic drugs in children and adolescents, in Italy, the prescription rate remains lower and stable over time. So far, adequate studies - to document the longterm efficacy and safety of psychotropic drugs for the pediatric population - are still missing, given that the current available research examines short-term duration in use. The treatment of psychiatric disorders in children requires a multimodal and multidisciplinary approach, in which medications seldom correspond to the primary approach for treatment. On the other hand, the studies on ADHD point out the evidence on psychotropic medications’ efficacy. Most prescriptions of psychotropic drugs for children and adolescents are considered "off label", i.e. the medications are prescribed in age ranges, dosage and with indications not approved by regulatory authorities. Moreover, children and adolescents taking psychiatric medications, more than adults, may be exposed to higher risks of adverse events such as metabolic and endocrine abnormalities associated with second-generation antipsychotic treatments. Data on long-term efficacy and safety of psychiatric medications is essential to help understand the risk-benefit ratio of psychotropic drugs in children and adolescents.

Keywords: Adolescents, psychotropic drugs, efficacy, safety, review

  1. [1] Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, Petersen I, et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. European Neuropsychopharmacology 2016; 26: 411-419.
  2. [2] Hartz I, Skurtveit S, Steffenak AK, Karlstad O, Handal M. Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. BMC Psychiatry 2016; 16: 12.
  3. [3] Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in denmark. Acta Psychiatrica Scandinavica 2014; 129: 221-231.
  4. [4] Weinstein SJ, House SA, Chang CH, Wasserman JR, Goodman DC, Morden NE. Small geographic area variations in prescription drug use. Pediatrics 2014; 134: 563-570.
  5. [5] Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. Journal of Child and Adolescent Psychopharmacology 2009; 19: 757-764.
  6. [6] Piovani D, Clavenna A, Cartabia M, Bonati M. Psychotropic medicine prescriptions in Italian youths: a multiregional study. European Child and Adolescent Psychiatry 2016; 25: 235-245.
  7. [7] Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351:h4320.
  8. [8] Clavenna A, Andretta M, Pilati P, Dusi M, Gangemi M, Gattoni MB, et al. Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatrics 2011; 11: 40.
  9. [9] Ivarsson T, Skarphedinsson G, Kornor H, Axelsdottir B, Biedilae S, Heyman I et al. The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis. Psychiatry Research 2015; 227: 93-103.
  10. [10] Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Systematic Review 2013; 6: CD002317.
  11. [11] Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Systematic Review 2012; 11: CD004851.
  12. [12] Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. The Lancet 2016; published online June 8 http:// DOI: 10.1016/S0140-6736(16)30385-313]StrawnJR,WelgeJA,WehryAM,KeeshinB,RynnMA.Efficacyandtolerabilityofantidepressantsinpediatricanxietydisorders:asystematicreviewandmeta-analysis.DepressionandAnxiety2015;32:149-157
  13. [14] Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for nonpsychotic disorders in children and adolescents: a review of the randomized controlled studies. European Neuropsychopharmacology 2011; 21: 600-620.
  14. [15] Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS One 2015; 10: e0117166.
  15. [16] Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opinion on Drug Metabolism & Toxicology 2011; 7: 591-608.
  16. [17] Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. The Journal of the American Medical Association 2016; 315: 1997-2008.
  17. [18] Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. Journal of the American Academy of Child and Adolescent Psychiatry 1992; 31: 29-33.
  18. [19] Armour A, Gottschlich MM, Khoury J, Warden GD, Kagan RJ. A randomized, controlled prospective trial of zolpidem and haloperidol for use as sleeping agents in pediatric burn patients. Journal of Burn Care & Research 2008; 29: 238-247.
  19. [20] Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attentiondeficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics 2009; 123: e770-e776.
  20. [21] Bonati M. Psicofarmaci nell’età evolutiva. Roma: Il Pensiero Scientifico Editore; 2015.
  21. [22] Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. American Journal of Health-System Pharmacy 2008; 65: 1029-1038.
  22. [23] Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 2006; 63: 332-339.
  23. [24] Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal 2009; 339: b2880.
  24. [25] Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neuroscienze & Therapeutics 2010; 16: 83-90.
  25. [26] Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology 2011; 21: 621-645.
  26. [27] De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 2011; 26: 144-158.
  27. [28] Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016; 73: 247-259.
  28. [29] Clavenna A, Bonati M. Safety and tolerability of medications for adhd. In: Spina E, Trifirò G, ed. Pharmacovigilance in Psychiatry. ADIS; 2016. 233-253.
  29. [30] Stein MA, Weiss M, Hlavaty L. ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics 2012; 9: 509-517.
  30. [31] Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for adhd. European Child and Adolescent Psychiatry 2011; 20: 17-37.
  31. [32] Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry 2009; 166: 992-1001.
  32. [33] Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attentiondeficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opinion on Drug Safety 2015; 1-9.
  33. [34] Shin J-Y, Roughead EE, Park B-J, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case study. BMJ 2016; 353:i2550.
  34. [35] Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 47: 209-218.
  35. [36] Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. Journal of Child and Adolescent Psychopharmacology 2014; 24: 426-434.
  36. [37] Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123: 611-616.
  37. [38] Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70: 740-749.
  38. [39] Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with adhd who divert or misuse their prescribed medications. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 408-414.
  39. [40] Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014 Feb;77(2):295-301
  40. [41] Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152-5

Antonio Clavenna, Laura Reale, Daniele Piovani, Maurizio Bonarti, Psicofarmaci in età adolescenziale in "RIVISTA SPERIMENTALE DI FRENIATRIA" 2/2016, pp 79-101, DOI: 10.3280/RSF2016-002006